Go Pro

Madhu Kumar Analyst Performance

Analyst at The Goldman Sachs Group

Madhu Kumar is a stock analyst at The Goldman Sachs Group in the medical sector, covering 14 publicly traded companies. Over the past year, Madhu Kumar has issued 1 stock ratings, including and buy recommendations. While full access to Madhu Kumar's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Madhu Kumar's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
33 Last 10 Years
Buy Recommendations
57.58% 19 Buy Ratings
Companies Covered
14 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy57.6%19 ratings
Hold27.3%9 ratings
Sell15.2%5 ratings

Out of 33 total stock ratings issued by Madhu Kumar at The Goldman Sachs Group, the majority (57.6%) have been Buy recommendations, followed by 27.3% Hold and 15.2% Sell.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
14 companies

Madhu Kumar, an analyst at The Goldman Sachs Group, currently covers 14 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
14 companies
100.0%

Madhu Kumar of The Goldman Sachs Group specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
14 companies
100.0%

Madhu Kumar's Ratings History at The Goldman Sachs Group

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
8/29/2025Boost Price Target$127.57$185.00Buy